Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 2 records in total 2
    records per page




    Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic

    Authors: Mozaffar Aznab

    doi:10.1101/2020.05.26.20102889 Date: 2020-06-01 Source: medRxiv

    Background: The aim of this study was investigation of COVID-19 MESHD disease and its outcome in cancer MESHD patients who needed treatment, in a 90-day period. Methods: Cancer MESHD patient who required treatment, were evaluated for potential COVID-19 MESHD infection in a 90-day period, starting from beginning of this epidemic in Iran, January, to April 19, 2020. For treatment of solid tumor MESHD patients, if they did not have symptoms related to COVID-19 MESHD, just chest X-ray was requested. If they showed COVID-19 MESHD related symptoms, High Resolution CT scan of lungs was requested. For hematology cancer MESHD patients, PCR test for COVID-19 MESHD infection was requested as well. Protection measures were considered for personnel of oncology wards. Results: In this study, 279 patients were followed up in this 90-day period. No COVID-19 MESHD infection was observed in 92 cases of breast cancer MESHD, 72 cases of colon cancer MESHD, 14 cases of gastric cancer MESHD and 12 cases of pancreaticobiliary cancer MESHD .However, in 11 cases of lung cancer MESHD, 5 cases brain tumors MESHD and 12 cases ovarian cancer MESHD; 3 case of COVID-19 MESHD were observed. In the hematology cancers MESHD group, which included 14 cases of Hodgkin Lymphoma MESHD, 23 cases of lymphoproliferative disorder MESHD, 12 cases of acute leukemia MESHD and 12 cases of multiple myeloma MESHD; three of COVID-19 MESHD were observed. Conclusion: Patients with cancer MESHD who need treatment can be treated by taking some measures. These measures include observing individual and collective protection principles in patients and health-care personnel, increasing patients awareness particularly about self-care behavior, performing a COVID-19 MESHD test, and taking a chest X ray, before the treatment starts

    Dynamic profile of severe or critical COVID-19 MESHD cases

    Authors: Yang Xu

    doi:10.1101/2020.03.18.20038513 Date: 2020-03-20 Source: medRxiv

    In December 2019, a cluster of acute respiratory illness MESHD, now known as SARS-CoV-2 pneumonia MESHD, occurred in Wuhan, China. World Health Organization (WHO) declared the rapidly spreading coronavirus outbreak a pandemic on March 11, 2020, acknowledging what has seemed clear for some time-the virus will likely spread to all countries on the globe. As of February 11, 2020, the Chinese Center for Disease Control and Prevention (China CDC) has officially reported that there are 2.0% (889) asymptomatic cases, 2.3% (1,023) death cases, and 80.9% mild cases among 44,672 confirmed cases. 51.4% (22,981) were male and 48.6% (21,691) were female. Lymphopenia MESHD, in particular T lymphopenia MESHD, was common among patients with SARS-COV-2 in the observation. A notable drop in CD4 HGNC and CD8 HGNC lymphocyte counts occurred early in the course of the syndrome and was associated with adverse outcomes. The appearing a phenomenon of lymphocyte depletion ( PLD HGNC PLD MESHD) suggested severe adverse outcomes. The outcome observed: 60% had discharged and 20% had die.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.